MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$18,126K
EPS
-$0.19
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
15,964
11,175
9,229*
8,454
General and administrative
3,333
3,702
2,495*
2,118
Total operating expenses
19,297
14,877
11,723
10,572
Loss from operations
-19,297
-14,877
-11,723*
-10,572
Interest income and other expense, net
2,047
1,784
440*
738
Change in fair value of warrant liability
-
-
-24,123*
-
Income (gain) before equity method investment
-17,250
-13,093
12,840*
-9,834
Loss from equity method investment
-709
-599
-890*
-323
Net (gain) income
-17,959
-13,692
11,950*
-10,157
Unrealized loss on marketable securities
-487
-334
-32*
29
Cumulative foreign currency translation adjustment
320
104
133*
59
Comprehensive (gain) income
-18,126
-13,922
12,051
-10,069
Basic EPS
-0.19
-0.15
0.158
-0.12
Diluted EPS
-0.19
-0.15
0.153
-0.12
Basic Average Shares
92,368,013
89,996,728
76,283,813
82,836,369
Diluted Average Shares
92,368,013
89,996,728
78,617,342
82,836,369
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive (gain) income
-$18,126K
(-129.68%↓ Y/Y)
Cumulative foreign
currency translation...
$320K
(156.00%↑ Y/Y)
Net (gain) income
-$17,959K
(-124.54%↓ Y/Y)
Unrealized loss on
marketable securities
-$487K
(-2463.16%↓ Y/Y)
Income (gain) before
equity method...
-$17,250K
(-126.71%↓ Y/Y)
Loss from equity
method investment
-$709K
(-82.26%↓ Y/Y)
Interest income and other
expense, net
$2,047K
(220.34%↑ Y/Y)
Loss from operations
-$19,297K
(-88.08%↓ Y/Y)
Total operating
expenses
$19,297K
(88.08%↑ Y/Y)
Research and development
$15,964K
(102.77%↑ Y/Y)
General and
administrative
$3,333K
(39.63%↑ Y/Y)
Buy us a coffee
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS)